HeartBeam, Inc. (BEAT) - Form 8-K Summary
Business Context and Reporting Period
HeartBeam, Inc., an emerging growth company incorporated in Delaware, filed this Current Report on Form 8-K on April 14, 2026, with the earliest event reported on that date. The filing details the entry into a material definitive agreement for an underwritten public offering of common stock. The offering closed on April 16, 2026.
Key Financial Metrics and Transaction Details
- Shares Issued: 12,500,000 shares of Common Stock.
- Public Offering Price: $0.80 per share.
- Underwriter Purchase Price: $0.744 per share.
- Gross Proceeds: Approximately $10.0 million (before underwriting discounts, commissions, and estimated offering expenses).
- Over-Allotment Option: Underwriter granted a 30-day option to purchase up to 1,875,000 additional shares.
- Underwriter Warrants: Warrants issued to purchase 5% of the total shares sold in the offering, exercisable immediately and valid for five years.
Material Changes and Use of Proceeds
The primary material change is the capital raise via the public offering. The Company intends to use the net proceeds for the following purposes:
- Support commercialization of its FDA-cleared 12-lead synthesized ECG system.
- Advance development of its 12-lead ECG extended-wear patch and heart attack detection initiatives.
- Enhance AI capabilities.
- Working capital and general corporate purposes.
Guidance, Outlook, and Restrictions
The filing does not provide specific financial guidance or revenue forecasts. However, it outlines significant restrictions and terms:
- Lock-Up Period: A 75-day lock-up period applies to the sale of specified securities. Officers and directors are also subject to lock-up agreements prohibiting the sale or disposition of shares during this period without underwriter consent.
- Regulatory Status: The offering was made pursuant to a registration statement on Form S-3 declared effective on March 17, 2026.
Investor Verification Checklist
- Verify the final net proceeds after deducting underwriting discounts and offering expenses.
- Confirm whether the underwriter exercised the 30-day over-allotment option for the additional 1,875,000 shares.
- Review the specific terms of the Underwriter Warrants (Exhibit 4.1) regarding exercise price and conditions.
- Monitor the Company's progress on the commercialization of the FDA-cleared 12-lead ECG system as a primary use of funds.
- Check for any subsequent filings regarding the expiration or early release of the 75-day lock-up period.